High Community Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Associated With Decreased Contact Tracing Effectiveness for Identifying Persons at Elevated Risk of Infection-Vermont.

COVID-19 SARS-CoV-2 Vermont contact tracing effectiveness

Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
03 10 2022
Historique:
pubmed: 25 6 2022
medline: 6 10 2022
entrez: 24 6 2022
Statut: ppublish

Résumé

Vermont contact tracing consistently identified people at risk for coronavirus disease 2019 (COVID-19). However, the prevalence ratio (PR) of COVID-19 among contacts compared with noncontacts when viral transmission was high (PR, 13.5 [95% confidence interval {CI}, 13.2-13.9]) was significantly less than when transmission was low (PR, 49.3 [95% CI, 43.2-56.3]).

Identifiants

pubmed: 35748711
pii: 6617336
doi: 10.1093/cid/ciac518
pmc: PMC9278248
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

S334-S337

Informations de copyright

Published by Oxford University Press on behalf of Infectious Diseases Society of America 2022.

Déclaration de conflit d'intérêts

Potential conflicts of interest. M. F. has received support from the Vermont Department of Health. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Auteurs

Brian F Borah (BF)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Vermont Department of Health, Division of Health Surveillance, Burlington, VT, USA.

Julia Pringle (J)

Vermont Department of Health, Division of Health Surveillance, Burlington, VT, USA.
Center for Preparedness and Response, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Michael Flaherty (M)

Vermont Department of Health, Division of Health Surveillance, Burlington, VT, USA.

John E Oeltmann (JE)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Patrick K Moonan (PK)

COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

Patsy Kelso (P)

Vermont Department of Health, Division of Health Surveillance, Burlington, VT, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH